SN
Therapeutic Areas
Scancell Pipeline
| Drug | Indication | Phase |
|---|---|---|
| iSCIB1+ (SCIB1) | Advanced Unresectable Melanoma | Phase 2/3 |
| Modi-1 | Advanced Solid Tumors (including Renal Cell Carcinoma) | Phase 1/2 |
Leadership Team at Scancell
PL
Phil L'Huillier
Chief Executive Officer
PL
Professor Lindy Durrant
Chief Scientific Officer
DN
Dr Nermeen Varawalla
Chief Medical Officer
DM
Dr Mandeep Sehmi
Head of Business Development
DC
Dr Callum Scott
Senior Vice President of Development
DS
Dr Samantha Paston
Head of Translational Research
DS
Dr Shamim Kazmi-Stokes
Head of Programme Management
PA
Philip Angell-Manning
Head of CMC
AH
Alex Hayward
Head of Finance